US2017312218A1PendingUtilityA1

Transmucosal delivery devices with enhanced uptake

63
Assignee: BIODELIVERY SCIENCES INT INCPriority: Jul 21, 2006Filed: Feb 10, 2017Published: Nov 2, 2017
Est. expiryJul 21, 2026(~0 yrs left)· nominal 20-yr term from priority
A61P 25/00A61P 29/00A61P 25/04A61K 9/0056A61P 25/30A61P 29/02A61K 9/006A61K 31/485A61K 31/4468A61K 9/7007A61K 31/445A61K 9/70
63
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides methods for enhancing transmucosal uptake of a medicament, e.g., fentanyl or buprenorphine, to a subject and related devices. The method includes administering to a subject a transmucosal drug delivery device comprising the medicament. Also provided are devices suitable for transmucosal administration of a medicament to a subject and methods of their administration and use. The devices include a medicament disposed in a mucoadhesive polymeric diffusion environment and a barrier environment.

Claims

exact text as granted — not AI-modified
1 . A method for enhancing direct transmucosal delivery of a fentanyl or fentanyl derivative to a subject, said method comprising:
 administering a bioerodable drug delivery device to an oral mucosal surface of a subject, the device comprising: a fentanyl or fentanyl derivative disposed in a mucoadhesive polymeric diffusion environment; and a barrier environment disposed relative to the polymeric diffusion environment such that a unidirectional gradient is created upon application to the mucosal surface and the fentanyl or fentanyl derivative is delivered to the subject.   
     
     
         2 - 45 . (canceled)

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.